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Cell surface adhesion molecules are thought to play an important part in estab-
lishingthe intercellular contacts that are necessary forimmunological reactions (1).
One suchadhesion pathway inman involves thelymphocyte function-associated an-
tigen (LFA-1),' one ofa family ofleukocyte cell surface proteins (LFA-1, Mac-1, p150,
95) that are heterodimers with a common (3 chain and distinct though homologous
a chains (1, 2). The principal ligand for LFA-1 seems to be the intercellular adhe-
sion molecule ICAM-1, a protein expressed on many differentiated cell types (3).
The LFA-1/ICAM-1 pathway mediates a variety ofcell-cell adhesions by T and B
lymphocytes, natural killer cells, granulocytes, and macrophages (1-5) and also ap-
pears tobe responsible for the homotypic cell adhesions shown by certain leukocyte-
derived cell lines in vitro (5).
Interactions betweencytotoxicT lymphocytes(CTL) and theirtarget cells involve
an initial phase ofeffector/target adhesion, detectable by rapid conjugate formation
in vitro, which is independent ofantigen-specific recognition (4). mAb blocking studies
indicate that this interaction involves two separate adhesion pathways (4, fi). One
is the effector LFA-1/target ICAM-1 pathway described above, the other is mediated
via theT cell-specificCD2 antigen (T11, LFA-2) interactingwith a widely distributed
adhesion protein, LFA-3 (7), on the target cell surface. Both pathways appear to be
required for optimal effector/target conjugation, and therefore might be important
accessories for CTL formation.
One ofthe best characterized CTL surveillance systems operative in man is that
which is specificallydirected againstEpstein-Barr virus (EBV), an agentwith onco-
genic potential in vivo (8) and with cell growth transforming ability for human B
cells in vitro (9). EBVspecific CTL, reactivated from memory T cells in the blood
of virus-immune donors, recognize EBVtransformed B lymphoblastoid cell lines
(LCL) in a HLA class I antigen-restricted manner (10).
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In studying the possible importance of this surveillance system as a defense against
EBVassociated tumors, we found that early passage cultures of virus-genome-posi-
tive Burkitt's lymphoma (BL) cell lines were not killed by HLA-matched EBVspecific
CTL in assays where EBVtransformed LCL derived from the normal B cells of the
same patients were clearly recognized (11). We postulated that this reflected the in
vivo selection of a malignant BL cell clone that was no longer sensitive to virus-
specific T cell surveillance.
The above result with BL cells could not be explained by any altered expression
of HLA class I antigens on the tumorcell surface (11) but in several cases it did corre-
late with an altered pattern ofvirus gene expression. Thus, certain of the EBV latent
gene products that are consistently found in all in vitro-transformed LCL were not
detectably expressed in the early passage BL cells, suggesting a downregulation of
those viral proteins providing the target antigens for virus-specific T cell recognition
(12). However, we noted that not every case in which BL cells escaped recognition
could be explained in this way. Thus, on serial passage a number of BL cell lines
showed a broadening of virus latent gene expression (and an accompanying change
in cell surface/growth phenotype) to that characteristic of LCL, yet certain of these
lines still remained insensitive to EBVspecific CTL killing (12). This showed that
the capacity of malignant BL cells to evade T cell surveillance was not based solely
on altered virus gene expression and suggested that some other feature ofthe tumor
cell phenotype was also important. Here we identify that second feature as altered
adhesion molecule expression.
Materials and Methods
Cell Lines.
￿
BL lines were established from EBV genome-positive BL biopsy samples and
grown in suspension culture in RPMI-1640 containing FCS as described (13). Initially all
BL cells grew as single cell suspensions, but on serial passage some lines moved towards a
more LCL-like growth pattern and cell surface phenotype. Lines could be grouped according
to their growth morphology and their expression of the following leukocyte differentiation
antigens: the BL-associated glycolipid antigen, BLA, the common acute lymphoblastic leukemia
antigen, CALLA (CD10), and the LCL-associated antigens Ki24, CD23, CD30, and CD39.
The phenotype grouping of BL cell lines, described in detail elsewhere (14), can be summa-
rized thus: (group I) single cell growth, BLA' CALLA' Ki24- CD23" CD30- CD39- ;
(group I/II) single cells/small clumps, BLA' CALLA' Ki24' CD23 - CD30- CD39- ;
(group II) medium/large clumps, BLA' CALLA' Ki24' CD23' CD30' CD39' ; (group
III) large clumps, BLA- CALLA- Ki24' CD23' CD30' CD39' .
LCL were generated from BL patients by EBVinduced transformation of normal circulating
B cells using the B95 .8 or QIMRWIL strain of virus. All LCL display the groupIII phenotype.
Surface Immuno,fluorescence and FACS Analysis. Adhesion molecule expression by BL lines
and LCL was analyzed by surface immunofluorescence labeling and flow cytofluorometry.
Cells were initially labeled with saturating concentrations ofmouse IgG mAbs, washed, and
further incubated with polyclonal FITC-conjugated goat anti-mouse IgG (Sigma, London,
England). The mAbs used were MHM24 and MHM23 (15) specifying the a and 0 chains,
respectively, of LEA-1 (both kindly provided by Professor A. J. McMichael, John Radcliffe
Hospital, Oxford, England), RRIA (3) specifying ICAM-1 and TS2/9 (7) specifying LEA-3
(both kindly provided by Dr. T Springer, Dana Faber Cancer Institute, Boston, MA). In
addition, the mAbs W6.32 (16) and A21BC1 (kindly provided by Dr. N. Ling, University
of Birmingham, England) specifying HLA class I and class II molecules, respectively, the
CD19 mAb 8EB1 (from Dr. Ling) and the CD20 mAb BI (obtained from Coulter Clone,
Luton, England) were used as reference reagents in the same experiments. Labeled cells were
analyzed using a FACS IV (Becton Dickinson & Co., Mountain View, CA) and results wereGREGORY ET AL.
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expressed as fluorescence/volume ratios, thus facilitating the comparison of cell lines with
slightly different cell size distributions. Mean fluorescence/volume ratios were calculated from
measurements offluorescence intensity and of 180° light scatter (proportional to cell volume)
from 20,000 individual cells as described (17). Background fluorescence was detected using
cells that had only received FITC-conjugated antibody during the labeling procedure. For
any one combination of cell line and mAb, repeated testing under the same conditions of
labeling gave highly reproducible values of the mean fluorescence/volume ratio.
Qualitative Homotypic Aggregation Assay.
￿
Cultured cells were dispersed by repeated gentle
pipetting, resuspended in RPMI-1640 containing 10% FCS and 20 mM Hepes (RPMI-10H)
and reseeded at 5 x 10' cells in 0.25 ml in 2-ml wells (Nunc, Roskilde, Denmark). To each
well was added 0.25 ml RPMI-l0H either alone or containing the mAbs 8EB1, MHM23,
MHM24, RRl/1 or TS2/9 at a saturating final concentration, generally 1 :100 dilution of as-
citic fluid. After 30 min, incubation at 37°C on a rocking platform operating at 80 cycles
per minute, homotypic adhesion was assessed visually by observation of cell clumps using
an inverted phase contrast microscope.
EBV-specific T Cells: Preparation and Use,in Conjugate Formation and Cytotoxicity Assays.
￿
EBV
specific, HLA class I-restricted CTL were reactivated from the blood ofvirus-immune indi-
viduals and expanded in IL-2 as described (17). The capacity of CTL to bind BL or LCL
targets was assessed in a FAGS conjugate assay (4, 6) . Briefly, 2.5 x 104 CTL effectors la-
beled with fluorescein diacetate (100 wg/ml) and 5 x 104 target cells labeled with hydrocthi-
dine (48 wg/ml) were cocentrifuged at 4°C in 50 wl RPMI-l0H in 12 x 75 mm plastic tubes
(Falcon Labware, Oxnard, CA). After a 6-min incubation in a 37°C water bath, the cell pellets
were resuspended by vigorous vortexing in 0 .8 ml cold (4°C) PBS containing 0.2% BSA,
and the cell suspensions were held on ice and analyzed immediately in the FACS IV. Some
assays were conducted in the presence ofsaturating concentrations ofthe mAbs 8EB1, MHM23,
MHM24, RRIA, and TS2/9 used either individually or in pairs. In other assays, target or
effector cells were pretreated with single mAbs and then excess antibody was removed by
washing before completion ofthe conjugate-forming assay in normal medium. Where EDTA
was used to inhibit Mg` -dependent conjugate formation (4), effectors and targets were
brought together in the presence of 5 mM EDTA. Conjugate formation was assayed by FACS
analysis; 10,000 or 20,000 total fluorescent events were collected, and the proportion of total
events emitting both red (from targets) and green (from effectors) fluorescence signals (i .e.,
CTL-target conjugates) was divided by the proportion of the totalcells emitting green signals
(i.e., the total effector population), thus indicating the percentage ofeffectors in a given CTL
population that had formed conjugates. "Background" conjugate formation was estimated
using effector/target cell mixtures that were not cocentrifuged, but rather dispersed immedi-
ately into 0.8 ml PBS/BSA . Background values of effector conjugate formation that ranged
from <1% to 6% were always subtracted from the observed results.
The lytic capacity of EBVspecific CTL towards HLA class I antigen-matched BL and
LCL targets was assessed by short-term "chromium-release assay (17).
Results
Expression ofAdhesion Molecules in Relation to BL Cell Surface/Growth Phenotype.
￿
Levels
of expression of LEA-1, ICAM-1, and LFA-3 were examined in BL cell lines that
had retained the single cell/small clump growth pattern and biopsy-like phenotype
(groups I, I/II) versus those BL lines that had changed with serial passage to grow
in large clumps and to express a more "lymphoblastoid" cell surface phenotype while
retaining the chromosomal translocation indicative of their malignant origin (groups
II, III; see Materials and Methods). The FACS profiles obtained from two represen-
tative group I/II cell lines (ELI BL, WW2 BL) in Fig. 1 indicate their very low ex-
pression of LFA-1 and ICAM-1 and the virtual absence of LEA-3 . In the same anal-
ysis, two representative group III lines (BL18, BL36)showed increased levels ofLFA-1
and dramatically higher expression of ICAM-1 and LFA-3. Fig. 1 also shows the1814
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FIGURE 1.
￿
Expression of adhesion molecules by BL cell lines ofgroup I/II (biopsy-like) and group
III (LCL-like) phenotypes. Surface immunofluorescence labeling was performed using mAbs
MHM24, MHM23, RRl/1, and TS2/9 to LFA-la, LFA-10, ICAM-1, and LFA-3, respectively.
Samples were analyzed on a FAGS IV using linear fluorescence intensity settings. The abscissa
of each graph is graduated in arbitrary units from 0 to 200 in increments of 20.
unusual profile obtained with one particular group III line, WW1 BL, where high
levels of LFA-1 and ICAM-1 were observed in the absence of detectable LFA-3 . A
total of 14 EBV + BL cell lines were analyzed in this way, each on at least two occa-
sions, and the complete results are presented as fluorescence/volume ratios in Table
I. Group I and I/II cell lines generally expressed low levels of LFA-1 and little or
no ICAM-1 and LFA-3, even though these same cellswere strongly labeled by mAbs
to other membrane proteins, such as HLA class I or class II antigens, CALLA, and
the pan-B cell markers CD19 and CD20 (Table I and data not shown). By contrast,
group III BL cell lines generally expressed LFA-1, ICAM-1, and LFA-3 at the same
high levels as are seen on EBVtransformed LCL, with the single exception ofWW1
BL which, as already illustrated, lacked LFA-3. Table I also includes, as an addi-
tional reference, the fluorescence/volume ratios obtained with an LCL derived from
an LFA-1-deficient patient (18); this line expressed ICAM-1 and LFA-3 but lacked
LFA-1 and grew predominantly as single cells.
Functional evidence regarding the involvement of adhesion molecules in the al-
tered growth pattern of group III BL cell lines was obtained using a qualitative cell
aggregation assay. As shown in Fig. 2, lines such as BL18 and BL36 formed well-
defined cell aggregates within 30 min of seeding into wells as a dispersed single cell
suspension . Of several mAbs tested for their ability to affect aggregation when in-
cluded in the culture medium, specific inhibition was observed both with the anti-
LFA-1 reagents (MHM23 and 24) and with the anti-ICAM-1 reagent (RRl/1); on
the other hand, mAbs to LFA-3, to HLA class II antigens, or to the pan-B cell marker
CD19 had no such effect. Precisely similar results were obtained using LCL cells
rather than group III BL cells in the same assay (data not shown).
Antigen-independent Adhesion ofEBV-specific CTL to BL Cells.
￿
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FIGURE 2 .
￿
Homotypic adhesion by two BL-derived cell lines (131,18, BL36) of group III pheno-
type. Dissociated cells were allowed to aggregate for 30 min either in medium alone(CONTROL)
or in medium containing mAbsMHM23 (aLFA-1), RRl/1 (ctICAM-1), or TS2/9 (aLFA-3) . Con-
trol cultures containing mAbs to CD19 or toHLA class II molecules did not affect aggregation .
mAb MHM24 (anti-LFA-la) produced the same effect as MHM23 (anti-LFA-I0) .
target lines and EBVspecific CTL from HLA-mismatched individuals were used
in short-term conjugate formation assays to measure the efficiency ofBL-CTL adhe-
sions that were independent of any antigen-specific (i .e ., HLA-restricted) recogni-
tion . Fig . 3 shows the results of an experiment comparing group 1/II and group IIIGREGORY ET AL .
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FIGURE 4 .
￿
mAb blocking ofeffector/target conjugate formation . EBVspecific HLA-mismatched
CTL were allowed to bind to the indicated BL and LCL targets in the presence ofeither medium
alone (CONT) or of mAbs MHM23, RRl/1 or TS2/9 against LFA-1, ICAM-1, and LFA-3, respec-
tively. In the same assay these effectors showed 50% conjugate formation with their autologous
target LCL .
BL lines in combinationwith the same mismatched effectors; thecorresponding LCL
from these particular BL patients are included as control targets for comparison .
The group I/II BL cell lines displayed significantly reduced conjugateforming ability
when compared either with the group III BL lines or with their control LCL. This
pattern of results was obtained on many occasions, with the level of conjugate for-
mation by group I/II BL cell lines usually being<25% of that shown by the corre-
sponding LCL. The conjugates being detected by FAGS analysis in this assay were
the result of cell-cell interactions mediated by adhesion molecules ; since conjugate
formationwas consistently abolished in thepresence ofacombination ofanti-LEA-1
and anti-LFA-3 mAbs but unaffected by the CD19 control mAb.
In further mAb blocking experiments, conjugate formation betweenLCL targets
andEBVspecific CTL was inhibited by N50% in the presence of either anti-LFA-1
or anti-ICAM-1 or anti-LFA-3 (37-LCL, Fig. 4 ; WW1LCL, Fig . 5) . Combinations
of anti-LFA-1 and anti-ICAM-1 were nomore effective than eithermAb alone, whereas
anti-LFA-1 and anti-LFA-3 gave complete inhibition ; interestingly, combinations of
anti-ICAM-1 and anti-LFA-3 also gave substantial inhibition, but this was never1818
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FIGURE 5 .
￿
Conjugate formation of EBVspecific HLA-mismatched CTL with WW1 BL and
WW1 LCL targets in the presence of individual anti-LEA-1, anti-ICAM-1, or anti-LEA-3 mAbs
(MHM23, RR1/1, and TS2/9, respectively) or with dual mAb combinations . Control conjugate
assays were performed either in the presence ofmedium alone (NONE) or with the CD19 mAb
(8EB1) . Conjugate formation was also performed in the presence of 5 mM EDTA either alone
or in combination with individual mAbs against LEA-1, ICAM-1, or LFA-3 . In the same assay
these effectors showed 45% conjugate formation with their autologous target LCL .
complete (WW1 LCL, Fig. 5) . Pretreatment oftarget or ofeffector cells, then removal
ofunbound mAbs before the assay, showed that anti-ICAM-1 and anti-LFA-3 medi-
ated their inhibition throughbinding to thetarget cells, anti-LFA-1 throughbinding
to the effectors (data not shown) . Such results are consistent with there being two
pathways of antigen-independent adhesion for LCL-effector conjugations, one in-
volving LFA-1 and ICAM-1, the other involving LFA-3 (see also references 4, 19) .
All group III BL cell lines (with the exception ofWW1 BL, see below) showed
the same sensitivity to mAb blocking of conjugate formation as did LCL (BL36,
Fig. 4) and therefore appeared to interact with CTL through both LFA-1 and LFA-3
pathways . In contrast, the lower but still significant levels of conjugate formation
that group I/II BL cell lines displayed was completely abrogated by anti-LFA-1, was
partially inhibited by anti-ICAM-1, and was unaffected by anti-LFA-3 (WW2 BL
and WAN BL, Fig . 4) . This indicates that all effector/target conjugation involving
group 1/II BL cell lines occurs through an LFA-1 mediated pathway, andnot through
LFA-3 . Analysis of conjugate formation by the unusual group III cell line, WW1
BL, showed that this followed the group I/II BL pattern, all conjugates being in-
hibited in the presence of anti-LFA-1 (Fig . 5) . In this context, Fig . 5 also shows the
results of assays conducted in the presence of 5 mM EDTA in an effort to impair
selectively the Mg" -dependent LFA-1 pathway (4) . Although conjugate formation
by WW1-LCL cells was, at best, only slightly reduced by EDTA alone, a combina-
tion of EDTA and anti-LFA-3 was completely inhibitory ; in contrast, EDTA alone
was able to prevent all conjugate formation by WW1 BL cells .
Relationship between Adhesion Molecule Expression, Conjugate Formation, and SensitivityGREGORY ET AL.
￿
1819
TABLE 11
BL Lines and Corresponding LCLs: Adhesion Molecule Expression, Conjugate
Formation, and Sensitivity to EBV-specific T Cell Cytotoxicity
' BL-derived cell lines at indicated passage numbers in vitro together with the corresponding
in vitro-transformed LCL from the same patients. Allo-LCL is an LCL from a normal donor
that shows no HLA class I antigen matching with the EBV-specific effector T cells shown.
t Expression of adhesion molecules is indicated by fluorescence/volume ratios as measured by
FACS. Cells were surface-labeled for ICAM-1 using mAb RR1/1 and for LFA-3 using TS2/9.
s EBV-specific HLA-mismatched effectors binding in short-term assays to the target cells in-
dicated. These same effectors showed 45% binding in the same assay to their autologous
target LCL.
II Results of5-h 5 'Cr-release cytotoxicity assays using EBV-specific effector T cells from three
HLA class I antigen-matched donors ; CM, SW, and KS: E/T ratios of 10:1 and 5:1 are
indicated.
ofBL cells to EBV-specific CTL-mediated Lysis.
￿
Ofseveral EBV+ BL cell lines found
to be insensitive to HLA-matched EBVspecific CTL (11), the BL72 and WW1 BL
lines were known to be expressing the full spectrum ofEBVlatent proteins and so
their lack ofrecognition could not be ascribed to downregulation ofthe viral target
antigens for CTL responses(12). In thepresent study, access to cryopreserved stocks
ofthe BL72 line allowed cells at passages 25, 80, and 140 to be tested in the same
experiment foradhesion molecule expression, forconjugate formation, and for sus-
ceptibility to lysis by three independent CTL preparations from the HLA-matched
EBVimmune donors CM, SW, and KS. The corresponding LCL derived from the
same patient (72-LCL) providesan important reference target in these same assays.
As shown in Table II, the increasing expression of ICAM-1 and of LFA-3 that was
observed on BL72 cells with increasing passage number was reflected both in the
relative efficiency with whichthese cells formed conjugates and in theirrelative sen-
sitivity to EBV-specific cytolysis. We noted in particular that, while BL72 cells in
passage 25 did express some ICAM-1 and did form detectable numbersofconjugates,
significant CTL-mediated lysis was not observed until later passages by which time
LFA-3 was also expressed.
A critical role for LFA-3 in EBV-specific cytolysis was more strongly indicated
by the results obtained in this same set of assays using WW1 BL target cells and
the corresponding WW1 LCL control (Table II). Even at the high passage number
used in this particular study, WW1 BL cellsdisplaying the group III phenotype and
Target
cell line'
Adhesion
ICAM-1
molecules)
LFA-3
Conjugate
formations
Lysis
CM-T
10:1
by
cells
5:1
EBV-specific
SW-T
cells
5:1
T cellsll
KS-T
10:1
cells
5:1
p25 4.1 0 .7 9.6 0 0 0 0 2
BL72 p80 13 .0 12 .9 22.8 7 4 0 15 10
p140 24.1 21 .5 46 .3 23 18 11 34 26
72-LCL 34.4 58.9 26 .0 37 27 18 47 44
WW1 131, p60 48.0 0.9 30 .0 5 3 1 8 4
WW1 LCL 21 .1 40.2 48.0 42 29 31 40 40
Allo LCL 20.8 48.2 44 .0 3 2 2 7 51820
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expressing the full spectrum of known EBVlatent proteins remained insensitive to
EBVspecific CTL. The very low level of WW1 BL killing observed in these and
in many other assays was neversignificantly different from that of HLA-mismatched
LCL included as control targets, while the WW1 LCL itself was always strongly
killed. Note that the WW1 BL target did form appreciable numbers of conjugates
with EBVspecific CTL (Table II), even when tested with the same HLA-matched
effector T cell preparations as were used in thecytotoxicity assays (data not shown),
yet clearly these conjugates did not lead to EBVspecific cytolysis of the target cells.
Discussion
EBV+ BL cells in very early passage display a homogeneous cell surface pheno-
type, like that of the original biopsy population, and a single cell pattern of growth.
With serial passage some, but not all, lines move towards a more "lymphoblastoid"
(i.e., LCL-like) pattern of cell surface markers and begin to grow in large clumps
(13). Where such changes occur, they appear to be directly inducedby a broadening
of expression of the resident EBV genome; thus certain EBVlatent proteins that
are downregulated in BL tumor cells in vivo may begin to be expressed in vitro
(14). The present study shows that one important, and hitherto unrecognized fea-
ture of this EBVinduced phenotypic change is a dramatic increase in expression
of the cell adhesion molecules LFA-1, ICAM-1, and LFA-3 from the very low levels
present on early passage cells (Fig. 1, Table I). Indeed, our results suggest that the
movement of BL cells towards a more aggregated pattern of growth in vitro simply
reflects the increased availability of surface LFA-1, and ICAM-1, i.e., those mole-
cules involved in homotypic cell adhesion (Fig. 2) . In most of the phenotypically
altered BL cell lines, LFA-1 ICAM-1, and LFA-3 appear to have been coordinately
upregulated; however the WW1 BL cell line was an exception in that it displayed
the classic group III (LCL-like) surface phenotype, grew in clumps, and expressed
high levels of both LFA-1 and ICAM-1 in the absence of detectable LFA-3 (Fig. 1,
Table I) .
Several recent papers examining the antigen-independent phase of CTL/target
interactions have identified effector LFA-1 and target ICAM-1 molecules as being
involved in one adhesion pathway, and effector CD2 and target LFA-3 molecules
in another (4, 6, 19). Here we show that group I and I/II BL cell lines retaining
a biopsy-like phenotype and expressing low levels of adhesion molecules, formed
conjugates with EBVspecific CTL much less efficiently than did group III BL cell
lines or LCLs (Fig. 3). Moreover, the conjugates formed by group I/II lines were
mediated entirely viaan LFA-1 pathway, and notvia LFA-3. In contrast, most group
III BL cell lines showed a pattern of conjugate formation that was indistinguishable
from that of LCL and that involved both the LFA-1 and the LFA-3 pathways. The
exception among group III lineswasagainWW1 BL, which is phenotypically LCL-
like in all respects other than LFA-3 expression, and which appeared to form con-
jugates by exclusive use of the LFA-1 pathway(s) operative for group I/II BL cell
lines. In these LFA-3-independent adhesions, it was interesting that the anti-ICAM-
1 mAbneverachieved the complete inhibitory effect shownby the anti-LFA-1 mAbs
(Figs. 4 and 5). Other studies have alreadyindicated thepossibility ofasecond target
cell ligand for LFA-1 (19) and the present work suggests that such a molecule is as
important as ICAM-1 in mediating conjugateformation by group I/II BL cell lines.GREGORY ET AL.
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The final set of experiments (Table II) reveal how reduced adhesion molecule ex-
pression andreducedconjugate formationby BL cells are reflected in terms oftumor
cell sensitivity to EBVspecific T cell cytolysis. In particular, the results resolve a
long-standing paradox from earlier studies, namely that certain BL cell lines (BL72
and WW1 BL) that had begun to express the full spectrum of EBVlatent proteins
in vitro nevertheless remained insensitive to lysis by HLA class I antigen-matched
EBVspecific CTL (11, 12). Thus, BL72 cells at passage 25, though already showing
an LCL-like patternofvirus gene expression, still expressed only lowlevels of ICAM-1
and were virtually negative for LFA-3; it was only when these molecules were up-
regulated on serial passage that EBVspecific lysis occurred. The results with the
other unusual line, WW1 BL, were even more instructive because here the target
cells' resistance to EBVspecificlysis was retained in late passage and correlated with
acontinuing downregulation of LFA-3. Conjugates formed with CTLeffectorsthrough
the LFA-1 pathway(s) alone are therefore insufficient to achievetarget cell lysis, even
when the appropriateviraltarget/HLA classI antigen complexis availableforspecific
interaction with the T cell receptor. This observation adds to the body of recent
evidence that suggests that LFA-3 binding to CD2 on the T cell surface is not just
providing adhesive stabilization of cell-cell contact but is also contributing to func-
tional activation of the effector T cell (20, 21), possibly by facilitating an interaction
between CD2 and the Tcell receptor complex itself(22). We do not yet know whether
the WW1 BL cell genome retains an intact LFA-3 coding sequence, but it may be
possible to use these particular cells as recipients in LFA-3 gene trunsfection experi-
ments to examine the functional role ofLFA-3 in mediatingTcell recognition andlysis.
Placing the present work in a wider context, we now consider that there are two
features of EBV+ BL tumor cells that guarantee their evasion of EBVspecific T cell
surveillance in vivo. The first is a downregulation of several, but not allof those EBV
latent proteins that could provide target antigens for the virus-specific CTLresponse
(14). The second is a downregulation of the cellular adhesion molecules that facili-
tate CTL/target interactions, and in particular of LFA-3 without which such inter-
actions appear not to achieve target cell lysis. Our present findings on group I and
I/II BL cell lines, which we consider close but not necessarily exact parallels of the
BL biopsy phenotype in vivo, have led us to examine adhesion molecule expression
directly on biopsy cells themselves. In our studies to date, we find that the tumor
cells do express very low levels of LFA-1 (see also reference 23), but do not express
detectable amounts either of ICAM-1 or of LFA-3 (Gregory, C. D., unpublished
results). Such downregulation of ICAM-1 and LFA-3 expression on EBV+ tumor
cells emerging in the face of virus-specific T cell surveillance may reflect the in vivo
selection of an immunoresistant malignant clone.
Summary
Some EBV+ BL cell lines continue to grow as single cells on in vitro passage,
show an unusually restricted expression ofEBVlatent genesand retain a BL biopsy-
like cell surfacephenotype(group I/II lines); others change to growth in aggregates,
show a broader pattern of virus latent gene expression, and develop a cell surface
phenotype more characteristic ofEBVtransformed LCL (group III lines). Here we
show that the cell surface adhesion molecules LFA-1, ICAM-1, and LFA-3 are ex-
pressed at very low levels, if at all, on group I/II lines and are coordinately upregu-1822
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lated as BL lines move towards group III. The change to growth in aggregates reflects
the increasing availability of LEA-1 and ICAM-1, the two ligands whose mutual in-
teraction underlies homotypic BL cell adhesion in vitro. The low levels of ICAM-1
and LFA-3 on group I/II BL cell lines are also associated with an impaired ability
to interact with EBVspecific CTL in the antigen-independent phase of effector/target
conjugation. mAb blocking studies show that the small number of conjugates that
are formed with group I/II BL targets involve the LEA-1/ICAM-1 adhesion pathway
but not the LFA-3 pathway; in contrast, both pathways contribute to the efficient
conjugate formation shown by group III BL or LCL targets. Earlier work identified
one group III line, WW1 BL, as unusual since it expressed the full spectrum ofEBV
latent proteins yet remained insensitive to lysis by EBVspecific CTL. Here we show
that this line has an anomalous pattern of adhesion molecule expression with high
levels of LEA-1 and ICAM-1 in the absence of detectable LEA-3. The WW1 BL cells
form conjugates with EBVspecific CTL through the LEA-1/ICAM-1 pathway, but
in the absence of a target LFA-3/effector CD2 interaction these conjugates do not
achieve target cell lysis. This may reflect an important role for target LEA-3 mole-
cules in activating EBVspecific CTL function. From these in vitro studies, we postulate
that downregulation of the adhesion molecules LEA-3 and ICAM-1 on EBV+ BL
underlies the ability of the malignant clone to evade EBVspecific T cell surveillance
in vivo.
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